Compare Nutrien Ltd (NTR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Tempus AI — how do they compare? Nutrien Ltd trades at $69.9 (market cap $33.52B), while Tempus AI trades at $70.49 (market cap $12.77B). The key difference: Nutrien Ltd is far larger — about 2.6× Tempus AI's market cap, and Nutrien Ltd pays a 3.14% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Tempus AI for 22 Days on average.
| NTR | TEM | |
|---|---|---|
Market Cap | $33.52B | $12.77B |
Volume | 1,154,412 | 8,980,490 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $83.94 | $99.28 |
52-Week Low | $53.64 | $41.55 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $45.32B | $13.40B |
Dividend Yield | 3.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.87, down 1.87% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 earnings of $2.61 per share, missing estimates, while revenue benefited from higher fertilizer prices. Analyst consensus remains moderately bullish with a $76.14 price target, though recent news highlights industry headwinds from potential Belarus potash imports.
The stock presents a value opportunity with reasonable P/E (14.16) and P/B (1.29) ratios, supported by strong cash flow generation. However, investors face risks from volatile fertilizer markets, competitive pressures, and cyclical agricultural demand. Near-term performance will depend on Q3 earnings results and management's strategic update at the November Investor Day.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
